Oncology
How today’s biotechs are helping us Stand Up To Cancer
In recognition of Stand Up To Cancer Day, a look at next-generation treatments that are on the verge of making it into clinical practice.
News
Bayer moves Hyrnuo into frontline lung cancer treatment
Bayer chases after Boehringer with an FDA approval for oral HER2 inhibitor Hyrnuo in previously untreated HER2+ lung cancer.
News
Amgen's Imdelltra scores again in small cell lung cancer
Amgen's Imdelltra and AstraZeneca's Imfinzi have improved survival compared to Imfinzi alone as first-line maintenance treatment for ES-SCLC.
News
BMS eyes role for new CAR-T in post-BCMA multiple myeloma
BMS' arlo-cel has shown activity in a trial that could underpin filings in multiple myeloma settings where the four main drug classes have failed.
News
FDA overrides adcomm and approves AZ's oral SERD
The FDA has gone against the advice of its own expert advisors and approved AstraZeneca's Etcamah as a frontline treatment for breast cancer.
News
Views & Analysis
Deep Dive
Editor's Picks
Editor's Picks
